Invivyd (NASDAQ:IVVD) Insider Sells $14,888.88 in Stock

Invivyd, Inc. (NASDAQ:IVVD) insider Robert Allen III sold 20,679 shares of the business’s stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $0.72, for a total value of $14,888.88. Following the completion of the sale, the insider owned 195,808 shares in the company, valued at $140,981.76. This represents a 9.55% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Invivyd Price Performance

NASDAQ IVVD opened at $0.95 on Friday. The stock has a market capitalization of $280.26 million, a PE ratio of -2.88 and a beta of 0.71. The business has a 50 day simple moving average of $0.78 and a two-hundred day simple moving average of $1.22. Invivyd, Inc. has a 1-year low of $0.48 and a 1-year high of $3.07.

Invivyd (NASDAQ:IVVD) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). The firm had revenue of $14.29 million during the quarter, compared to the consensus estimate of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. On average, analysts anticipate that Invivyd, Inc. will post -0.51 EPS for the current fiscal year.

Institutional Investors Weigh In On Invivyd

Several institutional investors have recently made changes to their positions in IVVD. Invesco Ltd. grew its holdings in Invivyd by 190.6% during the 1st quarter. Invesco Ltd. now owns 108,999 shares of the company’s stock valued at $66,000 after purchasing an additional 71,485 shares during the last quarter. AQR Capital Management LLC raised its position in Invivyd by 2,051.0% in the 1st quarter. AQR Capital Management LLC now owns 410,711 shares of the company’s stock worth $249,000 after purchasing an additional 391,617 shares during the period. Marshall Wace LLP bought a new stake in Invivyd in the second quarter worth about $158,000. Jane Street Group LLC bought a new stake in Invivyd in the second quarter worth about $147,000. Finally, Vanguard Group Inc. lifted its stake in Invivyd by 46.7% in the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock worth $6,339,000 after purchasing an additional 1,834,970 shares during the last quarter. Institutional investors own 70.36% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts recently weighed in on IVVD shares. Wall Street Zen cut shares of Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. BTIG Research reiterated a “buy” rating on shares of Invivyd in a research report on Tuesday, July 7th. Weiss Ratings restated a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. Finally, HC Wainwright restated a “buy” rating on shares of Invivyd in a report on Tuesday. Three analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $8.00.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.